LIVE
ISRG
Intuitive Surgical, Inc. · Healthcare
$406.78
-7.88% this month
VERSUS
⟷
COMPARE
SYK
Stryker Corporation · Healthcare
$307.80
-3.13% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
ISRG
3
SYK
2
Comparison scoreboard
ISRG LEADS 3/5AI Score
ISRG ✓50.7
SYK 49.0
1Y Return
ISRG -20.57%
SYK ✓-17.56%
Fwd P/E
ISRG 34.88
SYK ✓18.67
Target Up.
ISRG ✓+37.47%
SYK +23.89%
Op. Margin
ISRG ✓30.87%
SYK 17.82%
Metrics last refreshed: 6/20/2026
Quick take
ISRG vs SYK Stock Comparison: AI Score, Valuation, Performance and Upside
Intuitive Surgical and Stryker are both leading medical device companies with robotic surgery systems, but serving different surgical specialties. Intuitive dominates soft tissue robotic surgery with da Vinci; Stryker competes in robotic joint replacement with Mako. Intuitive's razor/razorblade installed base model creates exceptional recurring revenue. Stryker is more diversified across orthopedics, neurotechnology, and hospital equipment. Both are premium-quality medtech compounders.
ISRG vs SYK is the dominant soft tissue robotic surgery platform with razor/razorblade instrument revenue from 9,000+ installed systems (Intuitive Surgical) versus the diversified medtech leader with Mako robotic joint replacement and broad orthopedic, neurology, and hospital equipment portfolio (Stryker) — focused robotic surgery monopoly vs diversified medtech breadth.
Live analysis · updated 6/20/2026
ISRG holds the edge across 3 of 5 key metrics in this comparison. SYK leads on both 1-year return (-17.56%) and forward P/E (18.67x vs 34.88x for ISRG), a relatively favorable combination of momentum and valuation. ISRG leads on both revenue growth (23.00%) and operating margin (30.87%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ISRG (+37.47%) than for SYK (+23.89%).
Normalized 1Y performance
ISRG
SYK
Recent returns
ISRG
SYK
Analyst price targets & sentiment
ISRG · 28 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$350.00
analyst high$675.00
analyst mean$565.08
current price$406.78
+37.5% upside to analyst mean
SYK · 28 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.9/5.0)
Price target range
analyst low$306.00
analyst high$465.00
analyst mean$386.80
current price$307.80
+23.9% upside to analyst mean
Who should consider this stock?
ISRG may suit investors who:
- →prefer the razor/razorblade installed base compounding from 9,000+ da Vinci systems generating recurring instrument revenue from every robotic surgery procedure globally
- →value Intuitive's da Vinci 5 AI-assisted surgical guidance as the next generation platform extending the platform's clinical leadership
- →want the highest-quality single-product medtech moat — Intuitive's surgical robotics dominance in soft tissue is among the deepest medical device competitive advantages
- →are comfortable with competitor robotic surgery platforms gaining FDA approval, high capital equipment cost barriers to hospital adoption, and premium valuation reflecting quality
SYK may suit investors who:
- →prefer diversified medtech exposure across orthopedics (Mako robotics, implants), neurotechnology, and hospital medsurg equipment with multiple growth drivers
- →value Stryker's Mako robotic joint replacement leadership in a different but large surgical market than Intuitive's soft tissue focus
- →want medtech compounding from Stryker's proven acquisition strategy consistently adding innovative medical device companies
- →are comfortable with orthopedic elective procedure cyclicality, joint replacement competition from Zimmer and DePuy, and Intuitive's advantage in soft tissue robotic surgery
Performance & AI score
| Metric | ISRG | SYK |
|---|---|---|
| AI score | 50.7 | 49.0 |
| AI rank | #423 | #529 |
| Latest close | $406.78 | $307.80 |
| 1M return | -7.88% | -3.13% |
| 6M return | -26.95% | -12.70% |
| 1Y return | -20.57% | -17.56% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ISRG | SYK |
|---|---|---|
| 1Y ago | $7.98K (-20.2%) started 2025-06-18 | $8.25K (-17.5%) started 2025-06-18 |
| 5Y ago | $13.65K (+36.5%) started 2021-06-21 | $12.9K (+29.0%) started 2021-06-21 |
| 10Y ago | $56.49K (+464.9%) started 2016-06-20 | $32.64K (+226.4%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | ISRG | SYK |
|---|---|---|
| Market cap | $145.58B | $119.69B |
| Trailing P/E | 50.01 | 36.09 |
| Forward P/E | 34.88 | 18.67 |
| Price/Sales | 22.91 | 6.32 |
| EV/Revenue | 13.34 | 5.22 |
| Analyst target | $565.08 | $386.80 |
| Target upside | +37.47% | +23.89% |
Growth, profitability & risk
| Metric | ISRG | SYK |
|---|---|---|
| Revenue growth | 23.00% | 2.60% |
| Earnings growth | 18.80% | 14.20% |
| EPS growth | +18.80% | +14.20% |
| FCF margin | +21.30% | +17.25% |
| Operating margin | 30.87% | 17.82% |
| Profit margin | 28.15% | 13.21% |
| ROIC proxy | 17.23% | 15.20% |
| Return on equity | 17.23% | 15.20% |
| Dividend yield | N/A | 1.13% |
| Beta | 1.45 | 0.79 |
| Debt/equity | 0.95 | 66.30 |
| Current ratio | 4.61 | 2.11 |
| Quick ratio | 3.26 | 1.03 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
ISRG max drawdown32.16%
SYK max drawdown29.97%
ISRG max wkly drop8.79%
SYK max wkly drop11.59%
5Y risk snapshot
ISRG max drawdown49.90%
SYK max drawdown31.68%
ISRG max wkly drop22.30%
SYK max wkly drop13.06%
10Y risk snapshot
ISRG max drawdown49.90%
SYK max drawdown43.80%
ISRG max wkly drop22.30%
SYK max wkly drop23.64%
Performance metrics by period
| Period | Metric | ISRG | SYK |
|---|---|---|---|
| 1Y | Growth | -20.16% | -17.54% |
| CAGR | -20.19% | -17.56% | |
| Sharpe ratio | -0.73 | -0.92 | |
| Max drawdown | 32.16% | 29.97% | |
| Max daily drop | 6.67% | 6.47% | |
| Max wkly drop | 8.79% | 11.59% | |
| 5Y | Growth | +36.50% | +23.60% |
| CAGR | +6.43% | +4.34% | |
| Sharpe ratio | 0.22 | 0.11 | |
| Max drawdown | 49.90% | 31.68% | |
| Max daily drop | 14.34% | 8.04% | |
| Max wkly drop | 22.30% | 13.06% | |
| 10Y | Growth | +464.90% | +193.48% |
| CAGR | +18.92% | +11.37% | |
| Sharpe ratio | 0.56 | 0.37 | |
| Max drawdown | 49.90% | 43.80% | |
| Max daily drop | 14.34% | 13.11% | |
| Max wkly drop | 22.30% | 23.64% |
Business comparison
| Category | ISRG | SYK |
|---|---|---|
| Company | Intuitive Surgical, Inc. | Stryker Corporation |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Devices |
| Core business | Intuitive Surgical is the dominant robotic-assisted surgery company, operating the da Vinci surgical system with 9,000+ installed robot systems globally. Intuitive's business model is unique in medtech: it sells the da Vinci robot at relatively low margin but earns high-margin recurring revenue from instruments (replaced after 10 uses), accessories, and service contracts. Every surgical procedure on a da Vinci robot generates recurring instrument revenue. The da Vinci 5 (launched 2024) introduces AI-assisted surgical guidance. | Stryker is a broad-line medical device company providing orthopedic implants (Mako robotic joint replacement, hip and knee implants), neurotechnology (stroke treatment devices), and medsurg equipment (hospital beds, surgical tables, stretchers). Stryker's Mako robotic surgery system competes with Intuitive Surgical in the operating room — both are robotic-assisted, but Mako focuses on orthopedic joint replacement while Intuitive focuses on soft tissue procedures. Stryker's diversification across orthopedics, neurotechnology, and hospital equipment reduces single-product cyclical risk. |
| Investor focus | Investors track da Vinci procedures performed (the most important operating metric — driving instrument revenue), da Vinci 5 upgrade cycle, new system placements, and expansion of robotic surgery into new procedure categories. | Investors track orthopedic implant procedure volumes, Mako robotic system placements, neurotechnology revenue, and medsurg equipment growth as healthcare procedure volumes recover. |
ISRG strengths
- →Installed base razor/razorblade model: 9,000+ da Vinci systems create a recurring instrument revenue base that grows with every procedure — more procedures = more instrument revenue without new system sales
- →10-15 year institutional adoption cycles create switching costs — once a hospital training program is built on da Vinci, surgeons learn da Vinci controls, and replacing the platform disrupts surgical training
- →Procedure category expansion: urology, general surgery, gynecology, thoracic surgery all growing on da Vinci — each new procedure type multiplies addressable procedure volume
SYK strengths
- →Mako robotic joint replacement is the leading platform for robotic hip and knee replacement — a differentiated position in orthopedics that Intuitive Surgical cannot address with its soft-tissue focus
- →Diversified medical device portfolio across orthopedics, neurology, and hospital equipment provides multiple growth vectors with different cycle timing
- →Acquisitive growth strategy has consistently delivered value — Stryker's acquisition track record in medtech has been excellent at identifying and integrating innovative medical device companies
Risks to watch — ISRG
- →Medtronic Hugo, J&J Ottava, and CMR Versius compete in robotic surgery — the monopoly is eroding as competitors gain regulatory approvals
- →Da Vinci system capital cost ($1–2M per robot) is a barrier to hospital adoption — budget-constrained hospitals delay robotics purchases in economic downturns
- →Procedure per system growth required for instrument revenue to grow without proportional new system sales — maintaining procedure intensity is critical
Risks to watch — SYK
- →Orthopedic procedure volume correlates with healthcare utilization cycles — economic pressures delay elective joint replacement surgeries
- →Zimmer Biomet, Smith & Nephew, and DePuy Synthes compete in orthopedic implants with their own robotic platforms
- →Medical device inventory cycles at hospitals (hospitals over-ordering or under-ordering) create quarterly revenue variability
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
ISRG vs MDT
Which Medical Device Stock Wins?
BSX vs ISRG
Which MedTech Growth Stock Wins?
SYK vs ZBH
Which Orthopedic Device Stock Is Better?
ISRG vs GEHC
Robotic Surgery vs Imaging & AI Diagnostics
ISRG vs NVCR
Robotic Surgery vs Electric Field Cancer Therapy
EDAP vs IRTC
Cardiac Monitoring vs Sleep Apnea Device
More comparisons
Browse all 1,000 comparisons →